Clinical Trials

49 enrolled

Multiple Myeloma

NCT04166565 2026-04-20

EMN19

41 enrolled

Multiple Myeloma

NCT03763162 2026-04-15

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

40 enrolled

Multiple Myeloma

NCT04133636 2026-04-13

CARTITUDE-2

210 enrolled

Multiple Myeloma

NCT04181827 2026-04-13

CARTITUDE-4

419 enrolled 10 charts

Phase 1 Active not recruiting

Multiple Myeloma

NCT04722146 2026-04-13

MajesTEC-2

140 enrolled

Multiple Myeloma

NCT04923893 2026-04-13

CARTITUDE-5

743 enrolled

Multiple Myeloma

NCT05083169 2026-04-13

MajesTEC-3

587 enrolled 2 FDA

Multiple Myeloma

NCT05572515 2026-04-13

MajesTEC-9

614 enrolled

Multiple Myeloma, Recurrence

NCT06169215 2026-04-13

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

70 enrolled

Multiple Myeloma

NCT06577025 2026-04-13

aMMbition

43 enrolled

Multiple Myeloma

NCT03652064 2026-04-08

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 11 charts 2 FDA

Multiple Myeloma

NCT04512235 2026-04-07

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

281 enrolled

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04975997 2026-04-03

EXCALIBER-RRMM

939 enrolled

Multiple Myeloma

NCT04268498 2026-03-24

ADVANCE

310 enrolled

Multiple Myeloma

NCT02773030 2026-03-20

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

466 enrolled 57 charts

Multiple Myeloma, Recurrence

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

125 enrolled

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT05257083 2026-03-17

CARTITUDE-6

759 enrolled

Multiple Myeloma

NCT06353022 2026-03-17

IFm2022-01

103 enrolled

Multiple Myeloma

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

33 enrolled 11 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04802356 2026-03-05

Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

50 enrolled

Multiple Myeloma

NCT03729804 2026-03-04

(COBRA)

250 enrolled

Multiple Myeloma

NCT03589222 2026-02-27

SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

62 enrolled

Multiple Myeloma

NCT00378105 2026-02-24

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

68 enrolled 9 charts

Phase 1 Active not recruiting

Multiple Myeloma

NCT04754945 2026-02-18

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

11 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT03710603 2026-02-10

Perseus

709 enrolled 17 charts 2 FDA

Multiple Myeloma

NCT04751877 2026-02-10

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

270 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00572169 2026-02-05

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

177 enrolled

Multiple Myeloma

NCT03617731 2026-02-03

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

662 enrolled

Multiple Myeloma

NCT01208662 2026-01-22

DFCI 10-106

729 enrolled 29 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02718833 2026-01-22

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

52 enrolled

Multiple Myeloma, Recurrence

NCT04653246 2025-12-23

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

52 enrolled

Phase 4 Active not recruiting

Multiple Myeloma

NCT03829371 2025-12-03

STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

450 enrolled

Phase 1 Active not recruiting

Multiple Myeloma

NCT04091126 2025-11-28

DREAMM 9

118 enrolled

Multiple Myeloma

NCT05514990 2025-11-14

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

10 enrolled

Multiple Myeloma

NCT03004287 2025-09-10

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

50 enrolled

Multiple Myeloma

NCT01863550 2025-09-08

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

1,087 enrolled

Multiple Myeloma

NCT03314181 2025-08-14

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

156 enrolled

Multiple Myeloma, Neoplasms

NCT04052880 2025-07-20

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

17 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05123131 2025-07-08

Isa-RVD

54 enrolled

Multiple Myeloma

NCT04775550 2025-07-02

PRISM

61 enrolled

Multiple Myeloma

NCT00871013 2025-07-01

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

160 enrolled

Neoplasms, Plasma Cell

NCT00734877 2025-06-29

TT4B

382 enrolled

Multiple Myeloma

NCT00869232 2025-06-29

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

90 enrolled

Multiple Myeloma

NCT06956170 2025-06-11

DREAMM 8

21 enrolled 9 charts

Multiple Myeloma

NCT06868667 2025-05-09

DREAMM 7

24 enrolled 10 charts

Multiple Myeloma

NCT06868654 2025-04-23

DREAMM 7

72 enrolled 10 charts

Multiple Myeloma

NCT04484623 2025-03-18

DREAMM 8

302 enrolled 10 charts

Multiple Myeloma

NCT04717700 2025-03-18

SABLe

50 enrolled

Multiple Myeloma

NCT03989414 2024-11-29

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

424 enrolled